Associated Papers
Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity.
Okal EF et al.
Journal of Biological Engineering, 2025
39901286 (PubMed )
Supplement: 13036_2025_482_MOESM3_ESM.xlsx › table_for_paper
Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants.
MacGowan SA et al.
Plos Computational Biology, 2022
35235558 (PubMed )
Supplement: pcbi.1009922.s001.xlsx › Sheet1
An overview of human proteins and genes involved in SARS-CoV-2 infection.
Jahanafrooz Z et al.
Gene, 2022
SARS-CoV-2 receptor-binding mutations and antibody contact sites.
Mejdani M et al.
Antibody Therapeutics, 2021
34386694 (PubMed )
Supplement: Supplementary_Table_3_-_Full_bioinformatics_analysis_tbab015.xlsx › Nucleotide_Mutant_Frequency
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.
Suryamohan K et al.
Communications Biology, 2021
33846513 (PubMed )
Supplement: 42003_2021_2030_MOESM1_ESM.pdf
Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein.
Calcagnile M et al.
Biochimie, 2021
Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X et al.
Journal of Translational Medicine, 2020
32831104 (PubMed )
Supplement: 12967_2020_2486_MOESM1_ESM.xls › gnomAD_v2.1.1_ENSG00000130234_2
Select a paper to view details